Akari Therapeutics
$2.179876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.17
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.03 (+1.40%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours
Why Robinhood?
You can buy or sell AKTX and other stocks, options, and ETFs commission-free!
About AKTX
Akari Therapeutics plc ADR (0.01 USD), also called Akari Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.
CEO
Clive Stuart Richardson
Employees
10
Headquarters
London, London & South East
Founded
2004
Market Cap
73.49M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
549.17K
High Today
$2.20
Low Today
$2.11
Open Price
$2.15
Volume
93.86K
52 Week High
$4.21
52 Week Low
$1.42
AKTX Earnings
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 28, Pre-Market